Editorial: preclinical data reproducibility for R&D - the challenge for neuroscience

SpringerPlus

Volumn 4, Issue 1, 2015, Pages 1-4

  Steckler, Thomas ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84942273773     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-4-1     Document Type: Editorial

References (44)

1. Anderson DC, Kodukula K: Biomarkers in pharmacology and drug discovery.Biochem Pharmacol 2014, 87:172–188. 10.1016/j.bcp.2013.08.026
2. Begley CG, Ellis LM: Drug development: raise standards for preclinical cancer research.Nature 2012, 483:531–533. 10.1038/483531a
3. Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, Munafo MR: Power failure: why small sample size undermines the reliability of neuroscience.Nature Rev Neurosci 2013, 14:365–376. 10.1038/nrn3475
4. Chalmers I, Glasziou P: Avoidable waste in the production and reporting of research evidence.Lancet 2009, 374:86–89. 10.1016/S0140-6736(09)60329-9
5. Cyranoski D: China drugs head fired over article row.Nature 2013, 498:283. 10.1038/498283a
6. Fanelli D: How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data.PLoS ONE 2009, 4:e5738. 10.1371/journal.pone.0005738
7. Fang FC, Steen RG, Casadevall A: Misconduct accounts for the majority of retracted publications.Proc Natl Acad Sci USA 2012, 109:17028–17033. 10.1073/pnas.1212247109
8. Fitz NF, Cronican AA, Lefterov I, Koldamova R: Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”.Science 2013, 340:924.
9. Franco A, Malhotra N, Simonovits G: Publication bias in the social sciences: unlocking the file drawer.Science 2014, 345:1502–1505. 10.1126/science.1255484
10. Frantz S: Therapeutic area influences drug development costs.Nature Rev Drug Disc 2004, 3:466–467.
11. Ioannidis JPA: Why most published research findings are false.PLoS Med 2005, 2:e124. 10.1371/journal.pmed.0020124
12. Ioannidis JPA: How to make more published research true.PLoS Med 2014, 11:e1001747. 10.1371/journal.pmed.1001747
13. Kilkenny C, Parsons N, Kadyszewski E, Festing MFW, Cuthill IC, Fry D, Hutton J, Altman DG: Survey of the quality of experimental design, statistical analysis and experimental reporting of research using animals.PLoS ONE 2009, 11:e7824.
14. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates?Nature Rev Drug Disc 2004, 3:711–715. 10.1038/nrd1470
15. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD: A call for transparent reporting to optimize the predictive value of preclinical research.Nature 2012, 490:187–191. 10.1038/nature11556
16. Lazzeroni LC, Lu Y, Belitskaya-Levy I: P-values in genomics: apparent precision masks high uncertainty.Mol Psychiatry 2014. doi:10.1038/mp.2013.184
17. Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Al-Shahi Salman R, Khan AW, Glasziou P: Biomedical research: increasing value, reducing waste.Lancet 2014, 383:101–104. 10.1016/S0140-6736(13)62329-6
18. McNutt M: Journals unite for reproducibility.Science 2014, 346:678.
19. Mehta J: Preclinical Outsourcing Report: Long-Term and more Collaborative Contracts to Optimize Cost Structures. Contract Pharma; 2011. http://www.contractpharma.com/issues/2011–09/view_features/preclinical-outsourcing-report/
20. Michalek AM, Hutson AD, Wicher CP, Trump DL: The costs and underappreciated consequences of research misconduct: a case study.PLoS Med 2010, 7:e1000318. 10.1371/journal.pmed.1000318
21. Mobley A, Linder SK, Braeuer R, Ellis LM, Zwelling L: A survey on data reproducibility in cancer research provides insights into our limited ability to translate findings from the laboratory to the clinic.PLoS ONE 2013, 8:e63221. 10.1371/journal.pone.0063221
22. Moris F, Shackelford B: Extramural R&D Funding by U.S.-Located Businesses Nears $30 Billion in 2011. InfoBrief, NSF; 2014:14–314. http://www.nsf.gov/statistics/infbrief/nsf14314/nsf14314.pdf
23. Motulsky HJ: Common misconceptions about data analysis and statistics.Naunys Schmiedebergs Arch Pharmacol 2014. doi:10.1007/s00210–014–1037–6
24. Nature Editorial: Reducing our irreproducibility.Nature 2013, 496:398. (go.nature.com/oloeip)
25. Nature Editorial: Journals unite for reproducibility.Nature 2014, 515:7.
26. Nature Medicine Opinions: The yearbook.Nature Med 2013, 19:1561.
27. Normile D: Rieken shrinks troubled center.Science 2014, 345:1110. 10.1126/science.345.6201.1110
28. Nuzzo R: Statistical errors.Nature 2014, 506:150–152. 10.1038/506150a
29. O’Boyle EH Jr, Banks GC, Gonzalez-Mule E: The chrysalis effect: how ugly initial results metamorphosize into beautiful articles.J Manage 2014. doi:10.1177/0149206314527133
30. Peers IS, Ceuppens PR, Harbron C: In search of preclinical robustness.Nature Rev Drug Disc 2012, 11:733–734. 10.1038/nrd3849
31. Peers IS, South MC, Ceuppens PR, Bright JD, Pilling E: Can you trust your animal study data?Nature Rev Drug Disc 2014, 13:560.
32. Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DA, Golde TE, Felsenstein KM: Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”.Science 2013, 340:924.
33. Prinz F, Schlange T, Asadullah K: Believe it or not: how much can we rely on published data on potential drug targets?Nat Rev Drug Disc 2011, 10:712. 10.1038/nrd3439-c1
34. Schooler JW: Metascience could rescue the ‘replication crisis’.Nature 2014, 515:9. 10.1038/515009a
35. Selyukh A, Yukhananov A: FDA finds U.S. drug research firm faked documents. Reuters; 2011. http://uk.reuters.com/article/2011/07/26/health-us-fda-cetero-violation-idUKTRE76P7E320110726
36. Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D’Hooge R, De Strooper B: Comment on “ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models”.Science 2013, 340:924.
37. The Economist: Unreliable research: trouble at the lab.Economist 2013, 19th:26–30.
38. Tsilidis KK, Panagiotou OA, Sena ES, Aretoula E, Evangelou E, Howells DW, Salman RA-S, Macleod MR, Ioannidis JPA: Evaluation of excess significance bias in animal studies of neurological diseases.PLoS Biol 2013, 11:e1001609. 10.1371/journal.pbio.1001609
39. Van Noorden R: The trouble with retractions.Nature 2011, 478:26–28. 10.1038/478026a
40. Van Noorden R: Irish university labs face external audits.Nature 2014, 510:325. 10.1038/510325a
41. Vasilevsky NA, Brush MH, Paddock H, Ponting L, Tripathy SJ, LaRocca GM, Haendel MA: On the reproducibility of science: unique identification of research resources in the biomedical literature.PeerJ 2013, 1:e148.
42. Wahlsten D: Standardizing tests of mouse behavior: reasons, recommendations, and reality.Physiol Behav 2001, 73:695–704. 10.1016/S0031-9384(01)00527-3
43. Wahlsten D, Rustay NR, Metten P, Crabbe JC: In search of a better mouse test.Trends Neurosci 2003, 26:132–136. 10.1016/S0166-2236(03)00033-X
44. Wellcome Trust: Wellcome Trust Grant Conditions. 2013.